Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
Release Notes Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
PSORS2
MCID: PSR017
MIFTS: 58

Psoriasis 2 (PSORS2)

Categories: Genetic diseases, Immune diseases, Rare diseases, Skin diseases
Data Licensing
For inquiries, contact:
[email protected]
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Psoriasis 2

About this section

MalaCards integrated aliases for Psoriasis 2:

Name: Psoriasis 2 57 11 73 28 5 14 71
Psoriasis Vulgaris 73 71
Psoriasis 73 71
Psors2 57 73
Psoriasis, Susceptibility to, Type 2 38
Pv 73

Characteristics:


Inheritance:

Autosomal dominant 57

OMIM®:

57 (Updated 08-Dec-2022)
Miscellaneous:
variability in age of onset and severity of disease


Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases
Anatomical: Immune diseases Skin diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 11 DOID:0080475
OMIM® 57 602723
OMIM Phenotypic Series 57 PS177900
MeSH 43 D011565
MedGen 40 C1864497
UMLS 71 C0033860 C0263361 C1864497
Sources

Summaries for Psoriasis 2

About this section

UniProtKB/Swiss-Prot: 73 A common, chronic inflammatory disease of the skin with multifactorial etiology. It is characterized by red, scaly plaques usually found on the scalp, elbows and knees. These lesions are caused by abnormal keratinocyte proliferation and infiltration of inflammatory cells into the dermis and epidermis.

MalaCards based summary: Psoriasis 2, also known as psoriasis vulgaris, is related to psoriasis 6 and pustulosis of palm and sole, and has symptoms including pruritus, exanthema and psoriasiform rash. An important gene associated with Psoriasis 2 is CARD14 (Caspase Recruitment Domain Family Member 14). The drugs Infliximab and Metformin have been mentioned in the context of this disorder. Affiliated tissues include skin, liver and endothelial, and related phenotypes are hyperkeratosis and psoriasiform dermatitis

Disease Ontology: 11 A psoriasis that has material basis in heterozygous mutation in the CARD14 gene on chromosome 17q25.

More information from OMIM: 602723 PS177900
Sources

Related Diseases for Psoriasis 2

About this section

Diseases in the Psoriasis family:

Psoriasis 1 Psoriasis 3
Psoriasis 2 Psoriasis 4
Psoriasis 5 Psoriasis 6
Psoriasis 7 Psoriasis 9
Psoriasis 8 Psoriasis 10
Psoriasis 11 Psoriasis 12
Psoriasis 13 Psoriasis 15

Diseases related to Psoriasis 2 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1490)
# Related Disease Score Top Affiliating Genes
1 psoriasis 6 32.3 FBXL19 CARD14
2 pustulosis of palm and sole 31.9 CARD14 AP1S3
3 psoriasis 4 31.9 LCE3C LCE3B CARD14
4 impetigo herpetiformis 31.8 CARD14 AP1S3
5 geographic tongue 31.6 CARD14 AP1S3
6 psoriasis 15 31.5 SH3BP2 CARD14 AP1S3
7 psoriasis 3 31.3 LINC02693 FBXL19 CYTH1 CLMN CARD14
8 pityriasis rubra pilaris 30.5 CARD14 AP1S3
9 acrodermatitis 30.4 CARD14 AP1S3
10 psoriasis 1 29.8 LCE3C LCE3B CARD14
11 psoriasis 14, pustular 29.3 LCE3C LCE3B CARD14 AP1S3
12 psoriasis 29.2 LCE3C LCE3B FBXL19 CARD14 AP1S3
13 guttate psoriasis 11.6
14 tranebjaerg svejgaard syndrome 11.5
15 psoriatic juvenile idiopathic arthritis 11.5
16 psoriasis 10 11.4
17 psoriasis 5 11.4
18 periodontitis, aggressive, 1 11.4
19 psoriasis 12 11.4
20 psoriasis 8 11.4
21 psoriasis 15, pustular 11.4
22 psoriasis 9 11.4
23 skin disease 11.2
24 arthritis 11.2
25 juvenile rheumatoid arthritis 11.1
26 vitiligo-associated multiple autoimmune disease susceptibility 1 11.0
27 parapsoriasis 11.0
28 nail disorder, nonsyndromic congenital, 1 11.0
29 singleton-merten syndrome 1 11.0
30 autoinflammatory syndrome, familial, with or without immunodeficiency 11.0
31 acute generalized exanthematous pustulosis 10.9
32 mental retardation and psoriasis 10.9
33 subacute cutaneous lupus erythematosus 10.9
34 chronic recurrent multifocal osteomyelitis 10.9
35 autoimmune disease 10.9
36 fanconi-bickel syndrome 10.9
37 singleton-merten syndrome 10.9
38 combined cellular and humoral immune defects with granulomas 10.8
39 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 10.8
40 hypotrichosis-osteolysis-periodontitis-palmoplantar keratoderma syndrome 10.8
41 singleton-merten syndrome 2 10.8
42 primary cutaneous amyloidosis 10.8
43 glycogen storage disease due to lactate dehydrogenase deficiency 10.8
44 abdominal obesity-metabolic syndrome 1 10.7
45 skin carcinoma 10.7
46 spondylitis 10.7
47 lipid metabolism disorder 10.7
48 crohn's disease 10.6
49 vitiligo-associated multiple autoimmune disease susceptibility 6 10.6
50 inflammatory bowel disease 10.6

Graphical network of the top 20 diseases related to Psoriasis 2:



Diseases related to Psoriasis 2
Sources

Symptoms & Phenotypes for Psoriasis 2

About this section

Human phenotypes related to Psoriasis 2:

30
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 hyperkeratosis 30 HP:0000962
2 psoriasiform dermatitis 30 HP:0003765
3 epidermal acanthosis 30 HP:0025092
4 scaling skin 30 HP:0040189
5 parakeratosis 30 HP:0001036

Symptoms via clinical synopsis from OMIM®:

57 (Updated 08-Dec-2022)
Skin Nails Hair Skin Histology:
hyperkeratosis
epidermal acanthosis
parakeratosis
follicular plugging
alternating orthokeratosis and parakeratosis (in some patients)
more
Skin Nails Hair Skin:
plaque-like scaling skin lesions
erythrodermic psoriasis (in some patients)
pustular psoriasis (in some patients)
skin atrophy, diffuse, in older patients

Skeletal:
arthritis, psoriatic (in some patients)

Clinical features from OMIM®:

602723 (Updated 08-Dec-2022)

UMLS symptoms related to Psoriasis 2:


pruritus; exanthema; psoriasiform rash
Sources

Drugs & Therapeutics for Psoriasis 2

About this section

Drugs for Psoriasis 2 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 364)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Infliximab Approved Phase 4 170277-31-3
2
Metformin Approved Phase 4 1115-70-4, 657-24-9 4091
3
Tazarotene Approved, Investigational Phase 4 118292-40-3 5381
4
Dapsone Approved, Investigational Phase 4 80-08-0 2955
5
Vedolizumab Approved Phase 4 943609-66-3
6
Hydrocortisone succinate Approved Phase 4 2203-97-6 3643
7
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
8
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 3640 5754
9
Zinc cation Approved, Experimental, Investigational Phase 4 7440-66-6, 23713-49-7 32051
10
Cathine Approved, Experimental, Illicit, Vet_approved, Withdrawn Phase 4 14838-15-4, 492-39-7 131954576 4786 26934
11
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
12
Thalidomide Approved, Investigational, Withdrawn Phase 4 50-35-1 5426
13
Sodium citrate Approved, Investigational Phase 4 68-04-2 23431961
14
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
15
Fluticasone Approved, Experimental Phase 4 90566-53-3 4659387 5311101
16
Desoximetasone Approved Phase 4 382-67-2 5311067
17
Sorbitol Approved, Investigational Phase 4 69-65-8, 50-70-4 453 6251 5780
18
Clocortolone Approved Phase 4 34097-16-0, 4828-27-7 5311052
19
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
20
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
21
Ustekinumab Approved, Investigational Phase 4 815610-63-0
22
Levoleucovorin Approved, Experimental, Investigational Phase 4 68538-85-2, 58-05-9, 73951-54-9 149436 6006
23
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 4112 126941
24
Ixekizumab Approved, Investigational Phase 4 1143503-69-8
25
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
26
Calcipotriol Approved Phase 4 112965-21-6 5288783
27
Racepinephrine Approved, Vet_approved Phase 4 51-43-4, 329-65-7 838 5816
28
Clobetasol Approved, Experimental, Investigational Phase 4 25122-46-7, 25122-41-2 2791 5311051 32798
29
Adalimumab Approved, Experimental Phase 4 331731-18-1
30
Alefacept Approved, Investigational, Withdrawn Phase 4 222535-22-0
31
Capsaicin Approved Phase 4 404-86-4 1548943
32
Calcitriol Approved, Nutraceutical Phase 4 32222-06-3 5280453
33
Cholecalciferol Approved, Nutraceutical, Vet_approved Phase 4 67-97-0, 1406-16-2 5280795 10883523
34
Glycine Approved, Nutraceutical, Vet_approved Phase 4 56-40-6 750
35
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
36
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 22737-96-8, 68-26-8 5280382 445354
37
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
38
Trichostatin A Experimental Phase 4 58880-19-6 5562 444732
39 Antiprotozoal Agents Phase 4
40 Antiparasitic Agents Phase 4
41 Antimalarials Phase 4
42 Trace Elements Phase 4
43 Vasoconstrictor Agents Phase 4
44 Micronutrients Phase 4
45 Calciferol Phase 4
46 Hydrocortisone 17-butyrate 21-propionate Phase 4
47 Pharmaceutical Solutions Phase 4
48 Chelating Agents Phase 4
49 Anti-Bacterial Agents Phase 4
50 Anesthetics Phase 4

Interventional clinical trials:

(show top 50) (show all 1637)
# Name Status NCT ID Phase Drugs
1 The Influence of Adalimumab vs. Fumaric Acid Esters on Cardiovascular and Metabolic Risk Factors in the Therapy of Patients With Moderate to Severe Psoriasis Vulgaris Unknown status NCT01088165 Phase 4 Adalimumab treatment arm;Fumaric acid esters treatment group
2 A Phase4,Multicenter, Randomized,Double-blind,Double Dummy, Parallel Controlled Study Evaluating the Efficacy and Safety of Triptergium Wilfordii and Acitretin in Treatment of Chinese Patients With Moderate to Severe Psoriasis Vulgaris Unknown status NCT01443338 Phase 4 Triptergium Wilfordii;Acitretin
3 Secukinumab Therapy for the Treatment of Moderate to Severe Plaque Psoriasis With Response Monitoring Using Optical Coherence Tomography (OCT). Unknown status NCT03307447 Phase 4 Secukinumab
4 A Randomized Controlled Trial Comparing the Efficacy and Safety Profile of Oral Versus Subcutaneous Route of Methotrexate Administration in Moderate to Severe Psoriasis Unknown status NCT03408756 Phase 4 methotrexate
5 Metformin for Treatment of Psoriasis Combined With Disorders of Glucose and Lipid Metabolism: A Double-Blind, Randomized, Placebo-Controlled Study Unknown status NCT03629639 Phase 4 Metformin
6 A Phase 4 Multicenter, Randomized, Placebo-controlled Study Evaluating the Effect of Apremilast on Pruritus and Quality of Life of Patients With Moderate-to-severe Scalp Psoriasis Unknown status NCT03553433 Phase 4 Apremilast 30mg;Placebo Oral Tablet
7 Palmoplantar Psoriasis: Evaluating Efficacy and Clinical Photography With Brodalumab in Palmoplantar Psoriasis Unknown status NCT04622033 Phase 4
8 A Double - Blind, Placebo Controlled Crossover Study to Evaluate The Efficacy and Tolerability of Stelara ™ (Ustekinumab) in The Treatment of Scalp Psoriasis Unknown status NCT01558310 Phase 4 Ustekinumab;Placebo
9 The Difference of Circulating Endothelial-derived and Platelet-derived Microparticles in Patients With Psoriasis Successfully Treated With Stelara(Ustekinumab) Unknown status NCT02693470 Phase 4 Ustekinumab
10 Open Label Study, Evaluating Taltz in Combination With Enstilar (Calcipotriene and Betamethasone Dipropionate) Foam in Psoriasis Patients Unknown status NCT04372277 Phase 4 Enstilar
11 An Open-Label Study Evaluating Enstilar® (Calcipotriene and Betamethasone Dipropionate) Foam, 0.005%/0.064% QD in Psoriasis Patients Being Treated With Etanercept or Adalimumab Unknown status NCT03827876 Phase 4 Enstilar 0.005%-0.064% Topical Foam
12 A Single Center Study to Evaluate the Effectiveness and Safety of ILUMYA in Combination With HALOG Ointment 0.1% for the Treatment of Moderate to Severe Plaque Psoriasis. Unknown status NCT04347473 Phase 4 Ilumya Injectable Product
13 Open Label Study Evaluating DUOBRII in Psoriasis Patients Being Treated With Biologic Agents. Unknown status NCT04119102 Phase 4 Duobrii
14 Efficacy and Safety of Sorilux in Maintenance Treatment of Moderate Type Plaque Psoriasis After Combination Treatment of Lexette and Sorilux for 2 Weeks Unknown status NCT04571151 Phase 4 LEXETTE 0.05% Topical Foam;Sorilux 0.005 % Topical Foam
15 Phase IV Study on Efficacy and Safety of the Combination Treatment Acitretin and Efalizumab in Moderate to Severe Chronic Plaque Psoriasis Unknown status NCT00707070 Phase 4 efalizumab plus placebo;efalizumab plus acitretin
16 Improvement in the Quality of Life of Patients With Severe Plaque Psoriasis Treated With Systemic Methotrexate in Fixed Doses of 10mg or 25mg Orally Once Weekly: a Prospective, Randomized, Double-blind, Parallel Group Study. Unknown status NCT02248792 Phase 4 Methotrexate
17 Home UVB Phototherapy for Psoriasis: Effectiveness, Quality of Life and Cost-Effectiveness Unknown status NCT00150930 Phase 4
18 Multicenter Randomized Double Blind Controlled-study to Assess the Potential of Methotrexate Versus Placebo to Improve and Maintain Response to Anti TNF- Alpha Agents in Adult Patients With Moderate to Severe Psoriasis Unknown status NCT02829424 Phase 4 Methotrexate;Methotrexate Placebo
19 A Single Center Study to Evaluate the Effectiveness and Safety of Add on Enstilar® in Patients Using OTEZLA® for Moderate to Severe Plaque Psoriasis Unknown status NCT03587194 Phase 4 Otezla
20 An Open Label Trial to Show That Subjects With Severe Plaque-Type Psoriasis Receiving Acitretin 25 mg/Day And Stabilized On A Photochemotherapy Regimen Who Are Experiencing Retinoid-Related Adverse Events, Benefit From A Reduction In Acitretin Dose to 17.5 mg/Day, While Maintaining Comparable Efficacy Along With Improved Tolerability Unknown status NCT01228409 Phase 4 Acitretin 17.5 mg/day
21 Sensitivity and Specificity of QuantiFeron -TB Gold Test (QFT-G)in Comparison With Tuberculin Skin Test in Patients With Psoriasis and Psoriatic Arthritis Unknown status NCT01223976 Phase 4
22 Weight Reduction Alone May Not be Sufficient to Maintain Disease Remission in Obese Patients With Psoriasis: a Randomized, Investigator-blinded Study Unknown status NCT01439425 Phase 4
23 Apremilast in Combination With Clobetasol Spray for the Treatment of Plaque Psoriasis Unknown status NCT03453190 Phase 4
24 Prevalence, Pattern and Disease Course og Arthritis and Enthesitis in Patients With Psoriasis, and Effect of Apremilast in Subclinical, US-defined Psoriatic Arthritis - a Population Based Study Applying Clinical, Ultrasonic, MRI and Patient-reported Outcomes Unknown status NCT04515732 Phase 4 Apremilast Oral Tablet
25 Effect of Brodalumab Compared to Placebo on Vascular Inflammation in Moderate-to-severe Psoriasis Unknown status NCT03478280 Phase 4 Brodalumab;Placebos
26 Studying the Effect of Methotrexate Alone Versus Methotrexate and Vitamin D on the Cardiovascular Risk of Psoriatic Patients Unknown status NCT03904680 Phase 4 Methotrexate;Vitamin D
27 A Phase IV, Randomised, Multicentre, Double-blind, Study to Evaluate the Clinical Utility of Prospective Genetic Screening (HLA-B*1301) for Susceptibility to Dapsone Hypersensitivity Syndrome Unknown status NCT02550080 Phase 4 Dapsone
28 The Maintenance Effect of Enstilar Foam in Combination With Otezla Unknown status NCT04555707 Phase 4 Apremilast 30mg;calcipotriene and betamethasone dipropionate
29 Response to Ustekinumab for Anti-tnf Induced Psoriasiform Skin Lesions Unknown status NCT03629379 Phase 4 Ustekinumab;Vedolizumab
30 Efficacy of Combined Fractional Carbon Dioxide Laser and Topical Tazarotene in the Treatment of Psoriatic: Nail Disease a Single-blind, Intrapatient Left-to-right Controlled Study. Unknown status NCT03263624 Phase 4 Tazarotene Cream 0.1%
31 An Open-label Study to Evaluate the Efficacy of Re-treatment for Patients With a History of Etanercept Use Unknown status NCT01132235 Phase 4
32 Evaluation of Lymphocytic Infiltrate, Dendritic Cells and Cytokines Expression in Psoriatic Lesion and Normal Skin Before and After Adalimumab Therapy Unknown status NCT01237262 Phase 4 Adalimumab, etanercept, infliximab
33 Patient Preference of Taclonex Ointment to Taclonex Scalp Suspension in Adult Subjects With Psoriasis Vulgaris Completed NCT01707043 Phase 4 Taclonex
34 A Randomized Study Combining Etanercept and Short Courses of Narrow-Band UVB in Patients With Psoriasis Vulgaris Completed NCT00640393 Phase 4 Etanercept
35 A Trial That Compound Clobetasol Propionate Ointment Treats Patients With Mild to Moderate Psoriasis Vulgaris. Completed NCT02733874 Phase 4 Compound Clobetasol Propionate Ointment;Calcipotriol Betamethasone Ointment
36 Investigator Initiated Study for Optimal Maintenance Treatment With Calcipotriol /Betamethasone Dipropionate Gel in Korean Patients With Psoriasis Vulgaris Completed NCT02004574 Phase 4 Calcipotriol/betamethasone dipropionate gel
37 An Extension Study of Brodalumab in Subjects With Plaque Psoriasis (Psoriasis Vulgaris, Psoriatic Arthritis), Pustular Psoriasis (Generalized) and Psoriatic Erythroderma Completed NCT04183881 Phase 4 Brodalumab 210mg SC
38 Different Treatment Regimens of Calcipotriol Cream and Combination (Calcipotriol/Betamethasone Dipropionate) Ointment in Psoriasis Vulgaris Completed NCT00216892 Phase 4 Calcipotriol, (calcipotriol + betamethasone)
39 A Randomised, Double-Blind, Active-Controlled, Parallel, Multi-Center Study to Investigate the Efficacy and Safety of Daivobet® Ointment in Patients With Psoriasis Vulgaris Completed NCT00248456 Phase 4 Calcipotriol plus betamethasone dipropionate ointment
40 A Phase 4 Trial Comparing the Efficacy of Subcutaneous Injections of Brodalumab to Oral Administrations of Fumaric Acid Esters in Adults With Moderate to Severe Plaque Psoriasis Completed NCT03331835 Phase 4 Fumaric acid esters
41 An Investigator Initiated Open Label Study Evaluating the Efficacy and Tolerability of Oral Apremilast for the Treatment of Nail Psoriasis Completed NCT03022617 Phase 4 Apremilast
42 A Multicenter Open Label Uncontrolled Study of the Long Term Safety and Efficacy of Calcitriol 3 mcg/g Ointment Applied Twice Daily for 26 Weeks in Pediatric Subjects (2 to 16 Years and 11 mo of Age) With Mild to Moderate Plaque Psoriasis Completed NCT02125279 Phase 4 Calcitriol
43 Formulation and Clinical Evaluation of Ethosomal and Liposomal Preparations of Anthralin in Psoriasis Completed NCT03348462 Phase 4 ethosomal preparation of anthralin;liposomal preparation of anthralin
44 Long-term Treatment of Scalp Psoriasis With Xamiol® Gel in a Large Adult Chinese Population Completed NCT02533973 Phase 4 Xamiol® gel;Daivonex® scalp solution
45 Evaluation of Nail Psoriasis Severity Index (NAPSI) and Modified Napsi in Patients With Nail Psoriasis Treated With Acitretin Completed NCT00723437 Phase 4 acitretin
46 Comparison of the Performance of Subjective or Objective Psoriasis Severity Assessment Tools for the Assessment of the Improvement of Psoriasis After Oral Cyclosporine A or Methotrexate Treatment Completed NCT02655705 Phase 4 Cyclosporine A;Methotrexate
47 Randomised, Open-label Preliminary Study to Assess the Effects of 2 Regimens of Etanercept on Nail and Skin Symptoms in Patients With Nail Psoriasis and Plaque Psoriasis Completed NCT00581100 Phase 4 etanercept
48 A Multicenter, Open-Label, Post Marketing Clinical Trial to Evaluate the Efficacy And Safety Of Ixekizumab in Patients With Generalized Pustular Psoriasis and Erythrodermic Psoriasis Completed NCT03942042 Phase 4 Ixekizumab
49 A Single-Center, Open-Label Study to Assess Change in Psychosocial and Occupational Dimensions With Ustekinumab Treatment of Moderate-to-Severe Psoriasis Evaluated With the Psychological General Well Being (PGWB), Work Productivity and Activity Impairment (WPAI), Psoriasis Quality of Life-12 Items (PQOL-12), and Dermatology Life Quality Index (DLQI) Completed NCT01511315 Phase 4 Ustekinumab
50 A Randomized, Double-Blind Trial Assessing the Efficacy and Safety of Etanercept 50 mg Twice Weekly and Etanercept 50 mg Once Weekly for the Treatment of Moderate to Severe Psoriasis Completed NCT00663052 Phase 4 Etanercept

Search NIH Clinical Center for Psoriasis 2

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Acitretin
alefacept
Aloe vera preparation
Anthralin
ANTHRALIN PWDR
Betamethasone
Betamethasone acetate
Betamethasone benzoate
betamethasone dipropionate
betamethasone sodium phosphate
Betamethasone valerate
BETAMETHASONE VALERATE PWDR
calcipotriene
Calcitriol
Cholecalciferol
Coal Tar
Coal tar extract
Coal tar pitch volatiles
COAL TAR,COLLOIDAL
COAL TAR,REFINED
Cod Liver Oil
Colloid sulfur
Cyclosporine
Etretinate
Fish Liver Oils
fluocinolone
Fluocinolone Acetonide
hydroxyurea
Methotrexate
Methotrexate Sodium
Methoxsalen
mycophenolate mofetil
mycophenolate mofetil hydrochloride
Salicylic Acid
SALICYLIC ACID PWDR
Sulfur
SULFUR PWDR
SULFUR,COLLOIDAL
tazarotene
Thioguanine
Trioxsalen
Sources

Genetic Tests for Psoriasis 2

About this section

Genetic tests related to Psoriasis 2:

# Genetic test Affiliating Genes
1 Psoriasis 2 28 CARD14
Sources

Anatomical Context for Psoriasis 2

About this section

Organs/tissues related to Psoriasis 2:

MalaCards : Skin, Liver, Endothelial, T Cells, Neutrophil, Monocytes, Pituitary
ODiseA: Skin
Sources

Publications for Psoriasis 2

About this section

Articles related to Psoriasis 2:

(show top 50) (show all 30681)
# Title Authors PMID Year
1
PSORS2 is due to mutations in CARD14. 62 57 5
22521418 2012
2
Rare and common variants in CARD14, encoding an epidermal regulator of NF-kappaB, in psoriasis. 62 57 5
22521419 2012
3
Mapping of psoriasis to 17q terminus. 62 57 5
15689454 2005
4
Gene for familial psoriasis susceptibility mapped to the distal end of human chromosome 17q. 62 57 5
8178173 1994
5
Immune-regulatory genes as possible modifiers of familial pityriasis rubra pilaris - lessons from a family with PRP and psoriasis. 62 5
29704870 2018
6
CARD14-associated papulosquamous eruption: A spectrum including features of psoriasis and pityriasis rubra pilaris. 62 5
29477734 2018
7
Mutations in IL36RN in patients with generalized pustular psoriasis. 62 5
23648549 2013
8
A promoter sequence variant of ZNF750 is linked with familial psoriasis. 62 5
18256691 2008
9
PSORS2 markers are not associated with psoriatic arthritis in the Italian population. 62 57
16733365 2006
10
Analysis of RUNX1 binding site and RAPTOR polymorphisms in psoriasis: no evidence for association despite adequate power and evidence for linkage. 62 57
15923274 2006
11
Genetic analysis of PSORS2 markers in a UK dataset supports the association between RAPTOR SNPs and familial psoriasis. 62 57
15173233 2004
12
A putative RUNX1 binding site variant between SLC9A3R1 and NAT9 is associated with susceptibility to psoriasis. 62 57
14608357 2003
13
Novel immunoglobulin superfamily gene cluster, mapping to a region of human chromosome 17q25, linked to psoriasis susceptibility. 62 57
12483297 2003
14
Analysis of three suggested psoriasis susceptibility loci in a large Swedish set of families: confirmation of linkage to chromosome 6p (HLA region), and to 17q, but not to 4q. 62 57
9858851 1999
15
Evidence for two psoriasis susceptibility loci (HLA and 17q) and two novel candidate regions (16q and 20p) by genome-wide scan. 62 57
9259283 1997
16
Confirmation of genetic heterogeneity in familial psoriasis. 62 57
7562968 1995
17
Scanning chromosome 17 for psoriasis susceptibility: lack of evidence for a distal 17q locus. 62 57
7558055 1995
18
Injection site reactions due to the use of biologics in patients with psoriasis: A retrospective study. 62
36444279 2023
19
Evaluation of serum vascular endothelial growth factor level and findings of nailfold capillaroscopy by dermatoscope in the differential diagnosis of palmoplantar psoriasis and palmoplantar eczema. 62
36195239 2023
20
Efficient local delivery of FK506 using blocking patches in psoriasis. 62
36274404 2023
21
Examining worldwide postmarketing suicides from biologics used for psoriasis with a focus on brodalumab: A cross-sectional analysis using the Food and Drug Administration Adverse Event Reporting System (FAERS). 62
36248199 2022
22
The risk of COVID-19 in patients with psoriasis: A retrospective cohort study. 62
36305697 2022
23
Restless legs syndrome in patients with psoriasis: association with inflammation and sleep quality. 62
36468846 2022
24
Deucravacitinib in the treatment of psoriasis. 62
36453809 2022
25
Dupilumab-induced psoriasis in the setting of pembrolizumab therapy: an analysis of cytokine expression. 62
36468831 2022
26
Efficacy and Safety of Dimethyl Fumarate in Patients with Moderate-to-Severe Plaque Psoriasis: Results from a 52-Week Open-Label Phase IV Clinical Trial (DIMESKIN 1). 62
36456890 2022
27
Pustular Psoriasis. 62
36464467 2022
28
[[Translated article]]RF - Role of the Mediterranean Diet in the Treatment of Psoriasis. 62
36464008 2022
29
Commentary on a Clinical Trial of Spesolimab, a Humanized Anti-interleukin-36 Receptor Monoclonal Antibody, in Generalized Pustular Psoriasis. 62
36208408 2022
30
Pathogenesis, multi-omics research, and clinical treatment of psoriasis. 62
36209691 2022
31
Assessment of efficacy and safety of UV-based therapy for psoriasis: a network meta-analysis of randomized controlled trials. 62
34989291 2022
32
Maternal and neonatal outcomes of births to women with psoriasis: a population-based cohort of 13 million births. 62
34961404 2022
33
The epidermal immune microenvironment plays a dominant role in psoriasis development, as revealed by mass cytometry. 62
36348078 2022
34
Genetic variants in IL-17A rs10484879 and serum levels of IL-17A are associated with psoriasis risk. 62
34853870 2022
35
Low prevalence of patients diagnosed with psoriasis in Nuuk: a call for increased awareness of chronic skin disease in Greenland. 62
35467496 2022
36
ROS-sensitive calcipotriol nano-micelles prepared by methoxypolyethylene glycol (mPEG) - modified polymer for the treatment of psoriasis. 62
35748409 2022
37
Ustekinumab plus dupilumab in the treatment of concomitant psoriasis and prurigo nodularis. 62
35857380 2022
38
Artificial intelligence for the automated single-shot assessment of psoriasis severity. 62
35739649 2022
39
Female sexual dysfunction in psoriasis: a systematic review and meta-analysis using the Female Sexual Function Index. 62
36456639 2022
40
Psoriasis in the transplant population. 62
36459192 2022
41
Cytokine Modulators in Plaque Psoriasis - A Review of Current and Prospective Biologic Therapeutic Approaches. 62
36248203 2022
42
Disparities in psoriasis clinical trials: A cross-sectional analysis. 62
36113618 2022
43
Outcomes in Ixekizumab Patients Following Exposure to Secukinumab and Other Biologics in the CorEvitas Psoriasis Registry. 62
36331713 2022
44
Lenalidomide attenuates IMQ-induced inflammation in a mouse model of psoriasis. 62
36270258 2022
45
Anakinra for refractory pustular psoriasis: A phase II, open-label, dose-escalation trial. 62
36116584 2022
46
A Response to: Letter to the Editor Regarding Long-Term Benefit-Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysis. 62
36271222 2022
47
Practices and perspectives on medical cannabis and cannabinoids: A survey of the National Psoriasis Foundation Medical Advisory Board. 62
36017106 2022
48
The protective effect of proanthocyanidins on the psoriasis-like cell models via PI3K/AKT and HO-1. 62
36178125 2022
49
Biologics for psoriasis: is there any unmet need left? 62
36461935 2022
50
Subacute exposure to bisphenol F diglycidyl-ether (BFDGE) induces chronic dermatitis characterized by psoriasis-like skin inflammation in mice. 62
36453187 2022
Sources

Variations for Psoriasis 2

About this section

ClinVar genetic disease variations for Psoriasis 2:

5 (show top 50) (show all 652)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 CARD14 NM_001366385.1(CARD14):c.467T>C (p.Leu156Pro) SNV Pathogenic
 35573 rs387907240 GRCh37: 17:78157829-78157829
GRCh38: 17:80184030-80184030
2 CARD14 NM_001366385.1(CARD14):c.349+1G>A SNV Pathogenic
 280130 rs886041402 GRCh37: 17:78156590-78156590
GRCh38: 17:80182791-80182791
3 CARD14 NM_001366385.1(CARD14):c.349G>A (p.Gly117Ser) SNV Pathogenic
Pathogenic
 31606 rs281875215 GRCh37: 17:78156589-78156589
GRCh38: 17:80182790-80182790
4 CARD14 NM_001366385.1(CARD14):c.349+5G>A SNV Pathogenic
 31607 rs587777763 GRCh37: 17:78156594-78156594
GRCh38: 17:80182795-80182795
5 CARD14 NM_001366385.1(CARD14):c.425A>G (p.Glu142Gly) SNV Pathogenic
 31608 rs281875213 GRCh37: 17:78157787-78157787
GRCh38: 17:80183988-80183988
6 CARD14 NM_001366385.1(CARD14):c.424G>A (p.Glu142Lys) SNV Pathogenic
 31610 rs281875212 GRCh37: 17:78157786-78157786
GRCh38: 17:80183987-80183987
7 CARD14 NM_001366385.1(CARD14):c.371T>C (p.Leu124Pro) SNV Likely Pathogenic
 684676 rs1598639617 GRCh37: 17:78157733-78157733
GRCh38: 17:80183934-80183934
8 CARD14 NM_001366385.1(CARD14):c.449T>G (p.Leu150Arg) SNV Conflicting Interpretations Of Pathogenicity
 68781 rs146214639 GRCh37: 17:78157811-78157811
GRCh38: 17:80184012-80184012
9 CARD14 NM_001366385.1(CARD14):c.544C>T (p.Arg182Cys) SNV Uncertain Significance
 846189 rs372403419 GRCh37: 17:78157906-78157906
GRCh38: 17:80184107-80184107
10 CARD14 NM_001366385.1(CARD14):c.683T>G (p.Leu228Arg) SNV Uncertain Significance
 839822 rs142246283 GRCh37: 17:78162183-78162183
GRCh38: 17:80188384-80188384
11 CARD14 NM_001366385.1(CARD14):c.1805C>T (p.Ser602Leu) SNV Uncertain Significance
 527869 rs201285077 GRCh37: 17:78172344-78172344
GRCh38: 17:80198545-80198545
12 CARD14 NM_001366385.1(CARD14):c.16C>T (p.Arg6Cys) SNV Uncertain Significance
 840109 rs559363898 GRCh37: 17:78155253-78155253
GRCh38: 17:80181454-80181454
13 CARD14 NM_001366385.1(CARD14):c.1170C>A (p.Phe390Leu) SNV Uncertain Significance
 933837 rs74951924 GRCh37: 17:78165202-78165202
GRCh38: 17:80191403-80191403
14 CARD14 NM_001366385.1(CARD14):c.35C>T (p.Thr12Met) SNV Uncertain Significance
 662047 rs569889639 GRCh37: 17:78155272-78155272
GRCh38: 17:80181473-80181473
15 CARD14 NM_001366385.1(CARD14):c.348C>T (p.Ser116=) SNV Uncertain Significance
 659668 rs775819149 GRCh37: 17:78156588-78156588
GRCh38: 17:80182789-80182789
16 CARD14 NM_001366385.1(CARD14):c.1199G>A (p.Arg400His) SNV Uncertain Significance
 647550 rs147466598 GRCh37: 17:78165231-78165231
GRCh38: 17:80191432-80191432
17 SGSH, CARD14 NM_001366385.1(CARD14):c.2473G>A (p.Ala825Thr) SNV Uncertain Significance
 640610 rs538251591 GRCh37: 17:78178908-78178908
GRCh38: 17:80205109-80205109
18 CARD14 NM_001366385.1(CARD14):c.881C>T (p.Ala294Val) SNV Uncertain Significance
 444417 rs139466192 GRCh37: 17:78163589-78163589
GRCh38: 17:80189790-80189790
19 CARD14 NM_001366385.1(CARD14):c.203T>C (p.Met68Thr) SNV Uncertain Significance
 458092 rs773633754 GRCh37: 17:78155440-78155440
GRCh38: 17:80181641-80181641
20 CARD14 NM_001366385.1(CARD14):c.234G>T (p.Lys78Asn) SNV Uncertain Significance
 527867 rs143747620 GRCh37: 17:78156474-78156474
GRCh38: 17:80182675-80182675
21 SGSH, CARD14 NM_001366385.1(CARD14):c.2641G>A (p.Gly881Arg) SNV Uncertain Significance
 527870 rs548495951 GRCh37: 17:78179401-78179401
GRCh38: 17:80205602-80205602
22 CARD14 NM_001366385.1(CARD14):c.1356+4C>T SNV Uncertain Significance
 527885 rs373428751 GRCh37: 17:78166422-78166422
GRCh38: 17:80192623-80192623
23 CARD14 NM_001366385.1(CARD14):c.536G>A (p.Arg179His) SNV Uncertain Significance
 68783 rs199517469 GRCh37: 17:78157898-78157898
GRCh38: 17:80184099-80184099
24 SGSH, CARD14 NM_001366385.1(CARD14):c.2517G>C (p.Lys839Asn) SNV Uncertain Significance
 576948 rs950950885 GRCh37: 17:78178952-78178952
GRCh38: 17:80205153-80205153
25 CARD14 NM_001366385.1(CARD14):c.250G>A (p.Gly84Arg) SNV Uncertain Significance
 640077 rs193262780 GRCh37: 17:78156490-78156490
GRCh38: 17:80182691-80182691
26 CARD14 NM_001366385.1(CARD14):c.496C>T (p.Arg166Cys) SNV Uncertain Significance
 644802 rs751727290 GRCh37: 17:78157858-78157858
GRCh38: 17:80184059-80184059
27 SGSH, CARD14 NM_001366385.1(CARD14):c.2773G>A (p.Val925Ile) SNV Uncertain Significance
 650257 rs372586928 GRCh37: 17:78180850-78180850
GRCh38: 17:80207051-80207051
28 SGSH, CARD14 NM_001366385.1(CARD14):c.2956C>T (p.Arg986Cys) SNV Uncertain Significance
 658473 rs112478200 GRCh37: 17:78182085-78182085
GRCh38: 17:80208286-80208286
29 CARD14 NM_001366385.1(CARD14):c.205C>T (p.Arg69Trp) SNV Uncertain Significance
 662399 rs375624435 GRCh37: 17:78155442-78155442
GRCh38: 17:80181643-80181643
30 CARD14 NM_001366385.1(CARD14):c.484C>G (p.Leu162Val) SNV Uncertain Significance
 844790 rs1180184443 GRCh37: 17:78157846-78157846
GRCh38: 17:80184047-80184047
31 CARD14 NM_001366385.1(CARD14):c.433C>A (p.Gln145Lys) SNV Uncertain Significance
 847232 rs781101097 GRCh37: 17:78157795-78157795
GRCh38: 17:80183996-80183996
32 CARD14 NM_001366385.1(CARD14):c.1850T>C (p.Met617Thr) SNV Uncertain Significance
 850343 rs145521869 GRCh37: 17:78172389-78172389
GRCh38: 17:80198590-80198590
33 CARD14 NM_001366385.1(CARD14):c.1356+5G>A SNV Uncertain Significance
 861971 rs376524884 GRCh37: 17:78166423-78166423
GRCh38: 17:80192624-80192624
34 SGSH, CARD14 NM_001366385.1(CARD14):c.2735C>G (p.Thr912Ser) SNV Uncertain Significance
 944993 rs201965466 GRCh37: 17:78180812-78180812
GRCh38: 17:80207013-80207013
35 CARD14 NM_001366385.1(CARD14):c.1082G>A (p.Arg361Gln) SNV Uncertain Significance
 971793 rs763738345 GRCh37: 17:78164691-78164691
GRCh38: 17:80190892-80190892
36 SGSH, CARD14 NM_001366385.1(CARD14):c.2159G>A (p.Arg720His) SNV Uncertain Significance
 444418 rs202094920 GRCh37: 17:78176159-78176159
GRCh38: 17:80202360-80202360
37 CARD14 NM_001366385.1(CARD14):c.681T>G (p.Tyr227Ter) SNV Uncertain Significance
 808329 rs369755459 GRCh37: 17:78162181-78162181
GRCh38: 17:80188382-80188382
38 SGSH, CARD14 NM_001366385.1(CARD14):c.2591A>G (p.Tyr864Cys) SNV Uncertain Significance
 1374882 GRCh37: 17:78179351-78179351
GRCh38: 17:80205552-80205552
39 overlap with 4 genes NC_000017.10:g.(?_78032273)_(78163691_?)dup DUP Uncertain Significance
 1412377 GRCh37: 17:78032273-78163691
GRCh38:
40 CARD14 NM_001366385.1(CARD14):c.646G>A (p.Ala216Thr) SNV Uncertain Significance
 1441466 GRCh37: 17:78158008-78158008
GRCh38: 17:80184209-80184209
41 overlap with 4 genes NC_000017.10:g.(?_78010462)_(78158057_?)dup DUP Uncertain Significance
 1434129 GRCh37: 17:78010462-78158057
GRCh38:
42 CARD14 NM_001366385.1(CARD14):c.963+5C>T SNV Uncertain Significance
 1480972 GRCh37: 17:78163676-78163676
GRCh38: 17:80189877-80189877
43 CARD14 NM_001366385.1(CARD14):c.1012A>G (p.Met338Val) SNV Uncertain Significance
 1476693 GRCh37: 17:78164621-78164621
GRCh38: 17:80190822-80190822
44 SGSH, CARD14 NM_001366385.1(CARD14):c.2884C>T (p.Arg962Trp) SNV Uncertain Significance
 1347490 GRCh37: 17:78182013-78182013
GRCh38: 17:80208214-80208214
45 CARD14 NM_001366385.1(CARD14):c.1147G>T (p.Asp383Tyr) SNV Uncertain Significance
 1718475 GRCh37: 17:78165179-78165179
GRCh38: 17:80191380-80191380
46 CARD14 NM_001366385.1(CARD14):c.900G>C (p.Glu300Asp) SNV Uncertain Significance
 1714040 GRCh37: 17:78163608-78163608
GRCh38: 17:80189809-80189809
47 SGSH, CARD14 NM_001366385.1(CARD14):c.2639C>T (p.Ser880Phe) SNV Uncertain Significance
 1721061 GRCh37: 17:78179399-78179399
GRCh38: 17:80205600-80205600
48 SGSH, CARD14 NM_001366385.1(CARD14):c.1982A>T (p.Tyr661Phe) SNV Uncertain Significance
 1721109 GRCh37: 17:78175982-78175982
GRCh38: 17:80202183-80202183
49 SGSH, CARD14 NM_001366385.1(CARD14):c.2269A>T (p.Thr757Ser) SNV Uncertain Significance
 1715723 GRCh37: 17:78177670-78177670
GRCh38: 17:80203871-80203871
50 CARD14 NM_001366385.1(CARD14):c.1709C>A (p.Thr570Asn) SNV Uncertain Significance
 1719390 GRCh37: 17:78172248-78172248
GRCh38: 17:80198449-80198449

UniProtKB/Swiss-Prot genetic disease variations for Psoriasis 2:

73
# Symbol AA change Variation ID SNP ID
1 CARD14 p.Gly117Ser VAR_068224 rs281875215
2 CARD14 p.Glu138Ala VAR_068225 rs281875214
3 CARD14 p.Glu142Gly VAR_068226 rs281875213
4 CARD14 p.Glu142Lys VAR_068227 rs281875212
5 CARD14 p.Leu150Arg VAR_068228 rs146214639
6 CARD14 p.Arg69Trp VAR_078583 rs375624435
7 CARD14 p.Glu197Lys VAR_078588 rs200790561

Sources

Expression for Psoriasis 2

About this section
Search GEO for disease gene expression data for Psoriasis 2.
Sources

Pathways for Psoriasis 2

About this section
Sources

GO Terms for Psoriasis 2

About this section

Biological processes related to Psoriasis 2 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 killing of cells of another organism GO:0031640 8.92 LCE3C LCE3B
Sources

Sources for Psoriasis 2

About this section
2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....